Publications

Alcohol-related liver disease: a review

The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease

Unlocking recruitment with LiverPRO in a phase III pilot study for metabolic dysfunction-associated steatohepatitis

The sequential use of LiverPRO and ADAPT enhances fibrosis detection in at-risk populations (Poster ID: WED-131)

Phenotype-dependent failure of FIB-4 to rule-out advanced fibrosis among patients with MASLD in primary care: four-cohort comparison with LiverPRO

Metabolic matters: real-world assessment of metabolic dysfunction–associated steatotic liver diseases in the United States by integrating international classification of diseases codes and non-invasive tests for improved detection

LiverPRO prediction reflects fibrogenic activity in patients with metabolic dysfunction-associated steatohepatitis by identifying patients with elevated PRO-C3 (Poster ID: WED-219)

Implementing sustainable liver health in Europe: a second EASL–Lancet Commission

Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways

Steatotic liver disease trajectory: a holistic EASL guidance on the multidisciplinary approach to screening and patient management

LiverPRO reduces false positives and screening costs compared with Fibrosis-4 Index in steatotic liver disease

Simplified metabolic dysfunction Associated Fibrosis-5 (sMAF-5) score to identify at-risk liver fibrosis and to predict prognosis (Poster ID: PO1-03-YI)

A novel machine learning-based algorithm improves risk stratification of patients with MASLD compared to FIB-4 (Poster ID: PT2-01-YI)

External validation of a machine learning model for liver fibrosis risk assessment in U.S. representative adults (Poster ID: PO6-05-YI)

Evaluating non-invasive screening strategies for identifying treatment-eligible fibrotic MASH in MASLD patients (Poster ID: PO3-03-YI)

Blood-based non-invasive tests differentiate individuals with persistent liver stiffness elevation from those who normalise during follow-up: Longitudinal results from the LiverScreen consortium (Poster ID: OS-12-YI)

Reducing alcohol-associated liver disease burden in the general population

LiverPRO can optimize trial recruitment and lower screen failure rates in steatotic liver disease (Poster ID: 2016)

Design of a non-interventional study to estimate the prevalence of undiagnosed MASH using US real-world data through machine learning (Poster ID: 2152)

Prevalence of fibrosis and applicability of lab-based noninvasive tests from primary to tertiary care

Screening for advanced steatotic liver disease

Prescreening with a novel machine learning model (LiverPRO) may improve trial enrollment efficiency in metabolic dysfunction-associated steatohepatitis (MASH): a retrospective analysis of the SYNERGY-NASH trial (Poster ID: WED-420)

Performance of six biomarkers compared to liver biopsy as surrogate markers of clinical endpoints in drug trials of patients with MetALD and ALD (Poster ID: SAT-481-YI)

LiverPRO to diagnose and monitor liver fibrosis in patients with MASLD and obesity (Poster ID: WED-391)

Dynamics in lab-based non-invasive tests predict the development of liver-related outcomes in tertiary care (Poster ID: TOP-378-YI)

Decoding the dynamics: minimal detectable difference in non-invasive tests may exceed proposed thresholds for meaningful changes (Posted ID: WED-509)

Detecting at-risk steatotic liver disease and liver fibrosis in the community

Non-invasive tests for MetALD and alcohol-related liver disease

Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study

Enhancing trial recruitment in MetALD and ALD with LiverPRO to detect fibrosis (Poster ID: PO7-06)

Use of artificial intelligence for liver diseases: A survey from the EASL congress 2024

Replacing FIB-4 with LiverPRO as an initial test for detecting advanced fibrosis leads to a 6-fold reduction in false positive results (Poster ID: SAT_250)

Optimizing MASLD trial recruitment: LiverPRO vs. FIB-4 in reducing false positives and unnecessary biopsies (Poster ID: WED-199)

LiverPRO outperforms FIB-4 at predicting liver-related events in a cohort of 470,795 individuals

Algorithms for early detection of silent liver fibrosis in the primary care setting

New pathway shows a 73% reduction in mean-cost per patient while increasing the number of correct classifications

Only one-third of referrals for fatty liver disease are on time: real-world study reveals opportunities to avoid unnecessary and delayed referrals

Diagnostic accuracy of routine liver function tests to identify patients with significant and advanced alcohol-related liver fibrosis

Paired liver biopsies vs noninvasive tests as surrogate endpoints for clinical trials in metabolic and alcohol-related liver disease and alcohol-related liver disease